# Evercore Inc.: financial statements, quarterly EVR · NYSE · CIK 1360901 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/evr.md) · [Financials](/companies/evr/financials.md) · [Filings](/companies/evr/filings.md) · [Insiders](/companies/evr/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/evr/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [574](/filings/0001360901-24-000024.md) | [788 d](/filings/0001628280-26-010273.md) | [585](/filings/0001360901-25-000010.md) | [693](/filings/0001360901-25-000018.md) | [738](/filings/0001360901-25-000025.md) | [980 d](/filings/0001628280-26-010273.md) | [699](/filings/0001628280-26-031242.md) | [838](/filings/0001628280-26-053320.md) | [1,046](/filings/0001360901-25-000025.md) | [1,297 d](/filings/0001628280-26-010273.md) | [1,400](/filings/0001628280-26-031242.md) | [998](/filings/0001628280-26-053320.md) | | Interest expense | $m | [4.2](/filings/0001360901-24-000024.md) | [4.2 d](/filings/0001628280-26-010273.md) | [4.2](/filings/0001360901-25-000010.md) | [4.2](/filings/0001360901-25-000018.md) | [4.2](/filings/0001360901-25-000025.md) | [4.2 d](/filings/0001628280-26-010273.md) | [4.2](/filings/0001628280-26-031242.md) | [4.2](/filings/0001628280-26-053320.md) | [7.1](/filings/0001360901-25-000025.md) | [8.8 d](/filings/0001628280-26-010273.md) | [8.9](/filings/0001628280-26-031242.md) | [8.3](/filings/0001628280-26-053320.md) | | Income tax | $m | [19.7](/filings/0001360901-24-000024.md) | [27.6 d](/filings/0001628280-26-010273.md) | [(6.7)](/filings/0001360901-25-000010.md) | [28.4](/filings/0001360901-25-000018.md) | [35.0](/filings/0001360901-25-000025.md) | [58.7 d](/filings/0001628280-26-010273.md) | [(41.7)](/filings/0001628280-26-031242.md) | [44.3](/filings/0001628280-26-053320.md) | [59.8](/filings/0001360901-25-000025.md) | [90.8 d](/filings/0001628280-26-010273.md) | [9.1](/filings/0001628280-26-031242.md) | [41.1](/filings/0001628280-26-053320.md) | | Net income | $m | [52.1](/filings/0001360901-24-000024.md) | [82.7 d](/filings/0001628280-26-010273.md) | [85.7](/filings/0001360901-25-000010.md) | [73.8](/filings/0001360901-25-000018.md) | [78.4](/filings/0001360901-25-000025.md) | [140 d](/filings/0001628280-26-010273.md) | [146](/filings/0001628280-26-031242.md) | [97.2](/filings/0001628280-26-053320.md) | [145](/filings/0001360901-25-000025.md) | [204 d](/filings/0001628280-26-010273.md) | [301](/filings/0001628280-26-031242.md) | [95.3](/filings/0001628280-26-053320.md) | | Diluted EPS | $ per share | [1.30](/filings/0001360901-24-000024.md) | not reported | [2.09](/filings/0001360901-25-000010.md) | [1.81](/filings/0001360901-25-000018.md) | [1.86](/filings/0001360901-25-000025.md) | not reported | [3.48](/filings/0001628280-26-031242.md) | [2.36](/filings/0001628280-26-053320.md) | [3.41](/filings/0001360901-25-000025.md) | not reported | [7.20](/filings/0001628280-26-031242.md) | [2.32](/filings/0001628280-26-053320.md) | | Basic EPS | $ per share | [1.38](/filings/0001360901-24-000024.md) | not reported | [2.23](/filings/0001360901-25-000010.md) | [1.92](/filings/0001360901-25-000018.md) | [2.05](/filings/0001360901-25-000025.md) | not reported | [3.78](/filings/0001628280-26-031242.md) | [2.51](/filings/0001628280-26-053320.md) | [3.73](/filings/0001360901-25-000025.md) | not reported | [7.73](/filings/0001628280-26-031242.md) | [2.47](/filings/0001628280-26-053320.md) | - Revenue: us-gaap:Revenues - Interest expense: us-gaap:InterestExpense - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [493](/filings/0001360901-24-000024.md) | [597](/filings/0001628280-26-010273.md) | [570](/filings/0001360901-25-000010.md) | [632](/filings/0001360901-25-000018.md) | [533](/filings/0001360901-25-000025.md) | [873](/filings/0001628280-26-010273.md) | [553](/filings/0001628280-26-031242.md) | [617](/filings/0001628280-26-053320.md) | [852](/filings/0001360901-25-000025.md) | [1,426](/filings/0001628280-26-053320.md) | [986](/filings/0001628280-26-031242.md) | [1,257](/filings/0001628280-26-053320.md) | | Current assets | $m | [2,131](/filings/0001360901-23-000024.md) | [2,605](/filings/0001360901-25-000005.md) | [1,923](/filings/0001360901-24-000013.md) | [2,244](/filings/0001360901-24-000018.md) | [2,480](/filings/0001360901-24-000024.md) | [2,988](/filings/0001628280-26-010273.md) | [2,046](/filings/0001360901-25-000010.md) | [2,435](/filings/0001360901-25-000018.md) | [3,141](/filings/0001360901-25-000025.md) | [3,858](/filings/0001628280-26-053320.md) | [2,811](/filings/0001628280-26-031242.md) | [3,196](/filings/0001628280-26-053320.md) | | Total assets | $m | [3,226](/filings/0001360901-24-000024.md) | [3,703](/filings/0001628280-26-010273.md) | [3,006](/filings/0001360901-25-000010.md) | [3,316](/filings/0001360901-25-000018.md) | [3,568](/filings/0001360901-25-000025.md) | [4,174](/filings/0001628280-26-010273.md) | [3,271](/filings/0001628280-26-031242.md) | [3,690](/filings/0001628280-26-053320.md) | [4,422](/filings/0001360901-25-000025.md) | [5,358](/filings/0001628280-26-053320.md) | [4,314](/filings/0001628280-26-031242.md) | [4,701](/filings/0001628280-26-053320.md) | | Current liabilities | $m | [563](/filings/0001360901-23-000024.md) | [910](/filings/0001360901-25-000005.md) | [393](/filings/0001360901-24-000013.md) | [621](/filings/0001360901-24-000018.md) | [832](/filings/0001360901-24-000024.md) | [1,230](/filings/0001628280-26-010273.md) | [629](/filings/0001360901-25-000010.md) | [864](/filings/0001360901-25-000018.md) | [1,158](/filings/0001360901-25-000025.md) | [1,783](/filings/0001628280-26-053320.md) | [1,016](/filings/0001628280-26-031242.md) | [1,295](/filings/0001628280-26-053320.md) | | Total liabilities | $m | [1,571](/filings/0001360901-23-000024.md) | [1,921](/filings/0001360901-25-000005.md) | [1,358](/filings/0001360901-24-000013.md) | [1,588](/filings/0001360901-24-000018.md) | [1,788](/filings/0001360901-24-000024.md) | [2,232](/filings/0001628280-26-010273.md) | [1,519](/filings/0001360901-25-000010.md) | [1,771](/filings/0001360901-25-000018.md) | [2,337](/filings/0001360901-25-000025.md) | [3,038](/filings/0001628280-26-053320.md) | [2,226](/filings/0001628280-26-031242.md) | [2,522](/filings/0001628280-26-053320.md) | | Shareholders' equity | $m | [1,453](/filings/0001360901-23-000024.md) | [1,577](/filings/0001360901-25-000005.md) | [1,445](/filings/0001360901-24-000013.md) | [1,516](/filings/0001360901-24-000018.md) | [1,557](/filings/0001360901-24-000024.md) | [1,708](/filings/0001628280-26-010273.md) | [1,507](/filings/0001360901-25-000010.md) | [1,655](/filings/0001360901-25-000018.md) | [1,809](/filings/0001360901-25-000025.md) | [2,032](/filings/0001628280-26-053320.md) | [1,782](/filings/0001628280-26-031242.md) | [1,859](/filings/0001628280-26-053320.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [248 d](/filings/0001360901-24-000024.md) | [416 d](/filings/0001628280-26-010273.md) | [(281)](/filings/0001360901-25-000010.md) | [348 d](/filings/0001360901-25-000018.md) | [235 d](/filings/0001360901-25-000025.md) | [686 d](/filings/0001628280-26-010273.md) | [(550)](/filings/0001628280-26-031242.md) | [438 d](/filings/0001628280-26-053320.md) | [561 d](/filings/0001360901-25-000025.md) | [807 d](/filings/0001628280-26-010273.md) | [(226)](/filings/0001628280-26-031242.md) | [526 d](/filings/0001628280-26-053320.md) | | Capital expenditure | $m | [6.2 d](/filings/0001360901-24-000024.md) | [1.5 d](/filings/0001628280-26-010273.md) | [1.1](/filings/0001360901-25-000010.md) | [7.8 d](/filings/0001360901-25-000018.md) | [7.9 d](/filings/0001360901-25-000025.md) | [13.3 d](/filings/0001628280-26-010273.md) | [19.7](/filings/0001628280-26-031242.md) | [26.0 d](/filings/0001628280-26-053320.md) | [19.4 d](/filings/0001360901-25-000025.md) | [8.9 d](/filings/0001628280-26-010273.md) | [3.1](/filings/0001628280-26-031242.md) | [10.7 d](/filings/0001628280-26-053320.md) | | Dividends paid | $m | [28.8 d](/filings/0001360901-24-000024.md) | [28.8 d](/filings/0001628280-26-010273.md) | [43.2](/filings/0001360901-25-000010.md) | [30.9 d](/filings/0001360901-25-000018.md) | [30.8 d](/filings/0001360901-25-000025.md) | [30.9 d](/filings/0001628280-26-010273.md) | [46.5](/filings/0001628280-26-031242.md) | [32.6 d](/filings/0001628280-26-053320.md) | [32.8 d](/filings/0001360901-25-000025.md) | [32.5 d](/filings/0001628280-26-010273.md) | [49.8](/filings/0001628280-26-031242.md) | [34.9 d](/filings/0001628280-26-053320.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets - Dividends paid: us-gaap:PaymentsOfDividendsCommonStock ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [40.5](/filings/0001360901-23-000024.md) | [40.4](/filings/0001360901-24-000013.md) | [39.3](/filings/0001360901-24-000018.md) | [40.0](/filings/0001360901-24-000024.md) | [41.1](/filings/0001360901-25-000010.md) | [40.9](/filings/0001360901-25-000018.md) | [42.0](/filings/0001360901-25-000025.md) | [42.1](/filings/0001628280-26-031242.md) | [41.2](/filings/0001628280-26-053320.md) | [42.4](/filings/0001360901-25-000025.md) | [41.9](/filings/0001628280-26-031242.md) | [41.1](/filings/0001628280-26-053320.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.